Empaveli
Named-patient access overview. Empaveli is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Empaveli (pegcetacoplan) is a pegylated C3 complement inhibitor approved by the US Food and Drug Administration in May 2021 for adults with paroxysmal nocturnal hemoglobinuria (PNH). The product is marketed approximately by Apellis Pharmaceuticals. Pegcetacoplan targets the central complement protein C3, controlling both intravascular and extravascular hemolysis, and is delivered as a twice-weekly self-administered subcutaneous infusion. Its mechanism distinguishes it from terminal complement inhibitors that target C5.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Empaveli
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Empaveli is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Empaveli in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Empaveli
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.